The OS metastatic lesions in apatinib-treated mice were modestly reduced in terms of the luciferase intensity (Figs. 5C and S5B) and tumor-burdened volume (Figs. 5D and S5C), whereas a remarkable decline was observed in mice treated with the anti-VEGFR2 circuit. This evidence concerns the gene KDR and neoplasm.